BUSINESS BRIEF
A WHO-GMP certified Contract Development & Manufacturing Organization (CDMO) with integrated R&D and manufacturing capabilities is raising ₹40 Crore through a structured convertible loan instrument.
The company operates a 21,000 sq. ft. WHO-GMP compliant facility and has:
- Established commercial manufacturing operations
- 50+ skilled professionals including 40+ technical experts
- Blue-chip pharma clientele
- Strong IP portfolio with 55+ patents (20 granted)
- Clear IPO roadmap targeted for FY28-29
The business operates on a diversified four-pillar revenue model:
- Proprietary branded formulations
- CDMO manufacturing
- Fee-for-Service (FFS) R&D
- IP monetization & licensing
NOTE: The teaser specifies a ₹40 Crore Convertible Loan, not an immediate equity round.
Dilution % is not fixed upfront
Business Divisions
Manufacturing, Analytical R&D, Formulation R&D and Equipment
Products & Services
Tablets, Capsules, Oral Liquids, Topicals, Ophthalmics, Injectables
Proposal
Industry
Pharmaceuticals
Sub Industry
Pharmaceutical Manufacturing (Formulation) & Pharmaceutical Services (CDMO/CRAMS)
Nature of Business
B2B, B2B2C
Sector
Manufacturing (Contract Manufacturing)
Location
India
Region
Western
Open For Dilution
0 %
Top Customer
Ask
INR 40 Cr
End use of fund
- ₹25 Cr – Bank debt clearance (debt-free balance sheet)
- ₹5 Cr – Vendor & statutory normalization
- ₹5 Cr – Working capital
- ₹5 Cr – DCGI pipeline & product launches
Business Operation Information
Financial Information |
2025 (in INR Cr) | 2024 (in INR Cr) | 2023 (in INR Cr) |
|---|---|---|---|
Sales |
16.07 | 12.48 | 14.22 |
EBITDA |
|||
PAT |
